Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CNTB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $38.05M
- EPS (TTM)
- -$1.14
- Dividend yield
- None
- 52-week range
- 0.55 – 3.82
- Day range
- 0.5897 – 0.6378
- Volume / Avg
- 365.04K / 3.98M
- Beta
- —
- Shares outstanding
- 64.49M
52-week range
CNTB stock today
Connect Biopharma (CNTB) closed at $0.59 on Nov 20, down 6.08% (-$0.0382), versus the S&P 500's 3.70% decline. Trading was light, with 365.04K shares changing hands, about 9% of the average daily volume. Shares are 84.6% below their 52-week high of $3.82, set on Mar 27, 2026 and 7.3% above the 52-week low of $0.55, near the bottom of the past year's range.
CNTB is down 79.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.6%. Connect Biopharma has posted a net loss over the last twelve months (EPS of -$1.14), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Connect Biopharma
Company profileConnect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Barry David Quart Pharm.D.
- Headquarters
- San Diego, CA
- Employees
- 64
- IPO year
- 2021
- Website
- connectbiopharm.com
Financial highlights
Full financialsIn fiscal 2025, Connect Biopharma generated $64,000 in revenue, down 99.8% from fiscal 2024, the first decline in the 5 years shown. Connect Biopharma reported a net loss of $55.5 million, compared with a loss of $15.6 million a year earlier. Operating margin was -90740.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $64.00K | $26.03M | $0 | — | — |
| Growth | -99.75% | — | — | — | — |
| Net income | $-55.48M | $-15.63M | $-62.11M | $-118.09M | $-202.27M |
| EPS (diluted) | $-1.00 | $-0.28 | $-1.13 | $-2.15 | $-3.88 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$5.88+896.61%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.26 vs $-0.27
- Surprise
- +3.70%
CNTB news
All CNTB news- Connect Biopharma Holdings Limited Receives Nasdaq Minimum Bid Price Warning and Reports Third Quarter 2026 Financial ResultsNasdaqCNTB, LEN.B
- Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY LeadNasdaqAEMD, AZN, BBNX, BIIB
Connect Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SDEVStablecoin Development Corporation | 0.50 | -10.30% | $36.90M | vs CNTB |
| PLRXPliant Therapeutics Inc. | 0.5951 | -4.02% | $36.89M | vs CNTB |
| DWTXDogwood Therapeutics Inc. | 1.04 | -2.36% | $39.57M | vs CNTB |
| GRCEGrace Therapeutics Inc. | 1.71 | -0.58% | $35.97M | vs CNTB |
| TLPHTalphera Inc. | 0.7852 | +6.25% | $40.80M | vs CNTB |
| ELTXElicio Therapeutics Inc. | 1.45 | -3.33% | $41.05M | vs CNTB |
| CUECue Biopharma Inc. | 4.15 | -7.78% | $34.69M | vs CNTB |
| MREOMereo BioPharma Group plc ADR | 0.26 | -5.45% | $41.52M | vs CNTB |
Indexes, lists and sector
Connect Biopharma stock FAQ
What is Connect Biopharma's stock price today?
CNTB last traded at $0.59 as of Nov 20, 4:00 PM EST, down 6.08% on the day. Prices are delayed at least 15 minutes.
Who is Connect Biopharma's CEO?
Dr. Barry David Quart Pharm.D. is the chief executive officer of Connect Biopharma Holdings Limited, which has about 64 employees.
What is the CNTB 52-week high?
The 52-week high for CNTB is $3.82 and the 52-week low is $0.55. The stock is currently 84.6% below its high.